Product Images Azacitidine

This text provides information on the storage guidelines for Sterile Water for Injection, USP at different temperatures and durations. It suggests storing at room temperature (25°C / 77°F) for up to 1 hour or refrigerated at 2°C to 8°C (36°F to 46°F) for up to 8 hours. For cold storage (2°C to 8°C / 36°F to 46°F), it recommends refrigeration for up to 22 hours.*

This is the packaging information for a sterile single-dose vial containing azacitidine 100 mg and mannitol USP 100 mg. The vial should be discarded if unused and kept out of reach of children. It is for subcutaneous and intravenous use only, with storage instructions to keep it at 25°C (77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). The manufacturer is Reliance Life Sciences Pvt Ltd, located in Navi Mumbai, India. The barcode for the product is Reliance 7283.*

This text provides information about a medication called Azacitidine for Injection, which is contained in a single-dose vial. The medication is intended for subcutaneous and intravenous use only. It contains azacitidine 100 mg and mannitol USP 100mg. The text also includes storage instructions, prescribing information for dosing and administration, as well as details on manufacturing by Reliance Life Sciences in India.*

This is a brief text listing key abbreviations from a medical or scientific document. It mentions "AZA" which stands for azacitidine, "CCR" for conventional care regimens, "C1" for confidence interval, and "HR" for Hazard Ratio. These abbreviations seem to be related to a clinical study or trial.*

This data appears to be related to a research study or clinical observation involving the demographics, medical conditions, and treatments of a group of individuals. It includes information on gender distribution, race, age groups, specific medical conditions such as adenocarcinoma, and transfusion products used. The details seem to be categorized in percentages for gender, race, age groups, and usage of transfusion products within three months before the study entry.*

This text provides information about a medical evaluation related to complete response and partial response in a condition potentially related to bone marrow, blood cells, and blasts in the peripheral circulation. The text also mentions specific criteria related to the duration of 24 weeks and improvements in various parameters such as white cells, hemoglobin, and platelets in the blood. Additionally, a reduction in the white blood cell count is mentioned for a specific condition if it is elevated at the baseline.*

This document appears to be a list of medical conditions or disorders, including respiratory, thoracic, and mediastinal disorders, skin and subcutaneous tissue disorders, and vascular disorders. It includes terms such as dyspnea, pleuritic pain, erythema, pruritus, and hypertension, among others. The document also mentions that multiple reports of the same preferred term from two patients were only counted once within each treatment.*